Abstract 2789
Background
The Catalan Institute of Oncology (ICO) is a specialised cancer institution. It has four centres distributed around Catalonia that covers 45% of the adult cancer patient population in the autonomy. In three of them exists a radiotherapy department: L’Hospitalet, Badalona and Girona; with 11 accelerators altogether. Near 6.000 patients per year receive treatment in them. All radiotherapy departments in Spain need to accomplish with a quality system. ICO has a system based in International Organization for Standardization (ISO) regulations. Recently, a new system of ISO certification (ISO 9001:2015) has required increasing the homogenization level among our three departments. In addition, ICO promotes equality in access to services and assistance. For all these reasons it was developed the “Standardize project of the assistance procedures in Oncologic radiation”.
Methods
The ISO whole process was divided in 6 sub processes. In each center there was a group of professionals who works with every sub process and discuss with the other hospitals in order to define the common procedures. In February 2018, we started a work plan to do it through teleconference meetings. Nurses and radiotherapist technicians were included and nominate several leaders in each of the working groups which involved their activity. Meeting works ended in June 2018. From then until 2019 July we run with the implementation time.
Results
Nurses and radiotherapist technicians of the three institutions defined the list of agreements and consensus to do: homogeneous written education for patients to implement the active identification with patients Image guided radiotherapy protocols (IGRT) protocols for management break on treatments & short interruptions safety check list for the first session patient follow-up, alternating nurses and physicians nurse appointment at the end of treatments quality indicators for activity & schedules.
Conclusions
This project has assured that population from 3 different areas will receive same treatments, under equal circumstances. We incorporated strengths of each centre, using now a unique map of the process of radiotherapy. Furthermore we share same safety and prevention standards and a prospective system for risk analysis.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Institut Català d’Oncologia.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3252 - Genes involved in DNA replication, chromatin remodeling and cell cycle as potential biomarkers for therapy outcome to immune therapy in patients with metastatic cutaneous malignant melanoma
Presenter: Fernanda Costa Svedman
Session: Poster Display session 3
Resources:
Abstract
5545 - Phase Ib/II Study (SENSITIZE) assessing safety, pharmacokinetics (PK), pharmacodynamics (PD), and clinical outcome of domatinostat in combination with pembrolizumab in patients with advanced melanoma refractory/non-responding to prior checkpoint inhibitor therapy
Presenter: Jessica Hassel
Session: Poster Display session 3
Resources:
Abstract
5213 - Genomic landscape of primary malignant melanoma of esophagus
Presenter: Jie Dai
Session: Poster Display session 3
Resources:
Abstract
2716 - A phase III, randomised, double-blind study of adjuvant cemiplimab versus placebo post-surgery and radiation in patients with high-risk cutaneous squamous cell carcinoma (CSCC)
Presenter: Danny Rischin
Session: Poster Display session 3
Resources:
Abstract
3550 - ILLUMINATE 301: A randomized phase 3 study of tilsotolimod in combination with ipilimumab compared with ipilimumab alone in patients with advanced melanoma following progression on or after anti-PD-1 therapy
Presenter: Marcus Butler
Session: Poster Display session 3
Resources:
Abstract
1645 - PRIME002 - Early phase II study of Azacitidine and Carboplatin priming for Avelumab in patients with advanced melanoma who are resistant to immunotherapy
Presenter: Andre Van Der Westhuizen
Session: Poster Display session 3
Resources:
Abstract
4440 - Pembrolizumab (pembro) Plus Lenvatinib (len) for First-Line Treatment of patients (pts) With Advanced Melanoma: Phase 3 LEAP-003 Study
Presenter: Alexander Eggermont
Session: Poster Display session 3
Resources:
Abstract
3454 - Proof of concept study with the histone deacetylase inhibitor vorinostat in patients with resistant BRAFV600 mutated advanced melanoma
Presenter: Sanne Huijberts
Session: Poster Display session 3
Resources:
Abstract
1832 - A phase Ia/Ib clinical study to evaluate the safety, pharmacokinetics (PK) and preliminary anti-tumor activity of FCN-159 in patients with advanced melanoma harboring NRAS-aberrant (Ia) and NRAS-mutation (Ib).
Presenter: Lu Si
Session: Poster Display session 3
Resources:
Abstract
3996 - A Phase I Clinical Trial Investigating the Therapeutic Cancer Vaccine UV1 in Combination with Pembrolizumab as First-Line Treatment of Patients with Malignant Melanoma
Presenter: Sanjiv Agarwala
Session: Poster Display session 3
Resources:
Abstract